Large Gene panel helpful in identifying cancer-causing genes ANI | Updated: Feb 06, 2021 14:14 IST
Washington [US], February 6 (ANI): Researchers during a recent study have found a gene panel that includes all genes known to potentially cause cancer. This can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML.
The 523-gene panel, which looks about 10 times the number of cancer-causing genes, developed by San Diego-based biotech company Illumina, is currently used to diagnose and fine-tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia. The investigators reported in the journal PLOS ONE.
Credit: Kim Ratliff, Augusta University Photographer
AUGUSTA, Ga. (Feb. 1, 2020) - A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report.
The 523-gene panel, developed by San Diego-based biotech company Illumina, which includes all genes known to potentially cause cancer, can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML, the investigators report in the journal
PLOS ONE.
Identifying more genetic mutations in an individual s cancer also enables more targeted treatment for that patient, they say. That includes finding mutations not previously associated with their cancer type, which opens the door to using drugs targeting those mutations that have traditionally been used against other cancers.
Day Five of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness
January 18, 2021 19:00 ET | Source: Bionano Genomics Bionano Genomics San Diego, California, UNITED STATES
COVID-19 Host Genome Structural Variant (SV) Consortium used Saphyr to identify SVs in severe COVID-19 patients that affect genes involved in immunity, airway mucous, and viral replication
SVs found by several investigators point to a central role for disease severity of the interferon response pathway
Consortium has added investigators from Augusta University, Boston Children’s Hospital, New York Genome Center, Radboud University, Rockefeller University, UC San Diego, Virginia Commonwealth University, and two dozen other institutes from around the world
COVID-19 Host Genome SV Consortium Identifies Structural Variants with Possible Roles in Pathogenesis and Outcomes in Severely Ill COVID-19 Patients Using Bionano’s Saphyr® System First publication from international consortium highlights prowess of Saphyr in identifying large SVs with clinical significance and in COVID-19, an area with great public health implications
January 11, 2021 08:00 ET | Source: Bionano Genomics Bionano Genomics San Diego, California, UNITED STATES
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the first publication from the COVID-19 Host Genome Structural Variant Consortium. The study found that optical genome mapping (OGM) with Bionano’s Saphyr System identified structural variants (SVs) that affect genes in pathways that control immune and inflammatory response, viral reproduction and mucosal function. The authors believe these S